Skip to main navigation Skip to search Skip to main content

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

  • Eric Lawitz
  • , Mark Sulkowski
  • , Ira Jacobson
  • , Walter K. Kraft
  • , Benedict Maliakkal
  • , Mohamed Al-Ibrahim
  • , Stuart C. Gordon
  • , Paul Kwo
  • , Juergen Kurt Rockstroh
  • , Paul Panorchan
  • , Michelle Miller
  • , Luzelena Caro
  • , Richard Barnard
  • , Peggy May Hwang
  • , Jacqueline Gress
  • , Erin Quirk
  • , Niloufar Mobashery

Research output: Contribution to journal › Article › peer-review

30   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science